Peritoneal Carcinomatosis: Drugs and Diseases

1. Front Matter

   Pages i-xvi

   PDF

2. Pharmacology

   1. Intraperitoneal taxol

      • Maurie Markman

      Pages 1-5

   2. Early postoperative intraperitoneal Adriamycin as an adjuvant treatment for visceral and retroperitoneal sarcoma

      • Paul H. Sugarbaker

      Pages 7-14

   3. Intraoperative hyperthermic lavage with cisplatin for peritoneal carcinomatosis and sarcomatosis

      • Arvil D. Stephens, James F. Belliveau, Paul H. Sugarbaker

      Pages 15-30

   4. Intraperitoneal regional chemotherapy with mitroxantrone

      • Karl H. Link, G. Hepp, L. Staib, U. Butzer, W. Böhm, H. G. Beger

      Pages 31-40

   5. Treatment of peritoneal carcinomatosis by continuous hyperthermic peritoneal perfusion with cisplatin

      • H. Richard Alexander, Douglas L. Fraker

      Pages 41-50

   6. Surgically directed chemotherapy: Heated intraperitoneal lavage with mitomycin C

      • Vicente Fernández-Trigo, O. Anthony Stuart, Arvil D. Stephens, Louis D. Hoover, Paul H. Sugarbaker

      Pages 51-61

3. Disease States

   1. Pathobiology of peritoneal carcinomatosis from ovarian malignancy

      • Tessa A. Sugarbaker, David Chang, Patricia Koslowe, Paul H. Sugarbaker

      Pages 63-74

   2. Complete parietal and visceral peritonectomy of the pelvis for advanced primary and recurrent ovarian cancer

      • Paul H. Sugarbaker

      Pages 75-87

   3. Prognostic features for peritoneal carcinomatosis in colorectal and appendiceal cancer patients when treated by cytoreductive surgery and intraperitoneal chemotherapy

      • Paul H. Sugarbaker, David Chang, Patricia Koslowe

      Pages 89-104

   4. Pseudomyxoma peritonei

      • Paul H. Sugarbaker

      Pages 105-119

   5. Clinical determinants of treatment failure in patients with pseudomyxoma peritonei

      • Paul H. Sugarbaker, Vicente Fernández-Trigo, Falah Shamsa

      Pages 121-132

   6. Recurrent intraabdominal cancer causing intestinal obstruction: Washington Hospital Center experience with 42 patients managed by surgery and intraperitoneal chemotherapy

      • Andrew M. Averbach, Paul H. Sugarbaker

      Pages 133-147

   7. Peritoneal carcinomatosis: Natural history and rational therapeutic interventions using intraperitoneal chemotherapy

      • Paul H. Sugarbaker

      Pages 149-168

   8. Survival time and prevention of side effects of intraperitoneal hyperthermic perfusion with mitomycin C combined with surgery for patients with advanced gastric cancer

      • Shigeru Fujimoto, Makoto Takahashi, Takaaki Mutou, Kokuriki Kobayashi, Tadashi Toyosawa, Kimikazu Kondoh et al.

      Pages 169-176

   9. Intraperitoneal 5-fluorouracil and mitomycin C as adjuvants to resectable gastric cancer: A status report

      • Wansik Yu

      Pages 177-183

   10. Mechanism and treatment of peritoneal carcinomatosis: intraperitoneal chemotherapy with mitomycin C bound to carbon particles

       • Toshio Takahashi, Masataka Shimotsuma, Akeo Hagiwara, Toshiharu Yamaguchi

       Pages 185-192

   11. Peritoneal mesothelioma: Treatment approach based on natural history

       • Andrew M. Averbach, Paul H. Sugarbaker

       Pages 193-211

   12. Pathology of peritoneal mesothelioma

       • Mary E. Kass

       Pages 213-225

   13. Adjuvant hyperthermic intraperitoneal chemotherapy for adenocarcinoma of the pancreas

       • Stephen E. Ettinghausen, Andrew M. Averbach

       Pages 227-237

Peritoneal carcinomatosis dominates the clinical picture of many patients with gastrointestinal, gynecological and urological cancers. For many of them its dev­ astating effects contribute directly to their death. Most clinicians consider peritoneal carcinomatosis an incurable metastatic disease and give palliative treatment, re­ stricted to limited surgery and systemic chemotherapy. Contrary to this view, Paul Sugarbaker and his collegues base their approach on the concept that peritoneal carcinomatosis represents regional tumor spread, similar in its impact on treatment and prognosis to that of lymph node metastases in other malignancies. This concept emphasises the value of regional tumor control, as a potentially curative measure. In this book the combination of aggressive cytoreduction and intraperitoneal chemotherapy to control peritoneal carcinomatosis is extensively explored. Basic to this approach is the observation that most cancer cells show only relative resistence against commonly available drugs, which can be overcome by a sufficient increase of drug concentrations in tumor tissue. After intraperitoneal delivery, drugs will reach high tissue concentrations in the superficial few cell layers, while plasma concentrations will remain below toxic levels. Patients with only limited residual tumor at the peritoneal surface after cytoreduction may therefore benefit from intraperitoneal chemotherapy.

• carcinoma
• gastric cancer
• immunotherapy
• mesothelioma
• metastasis
• pathology
• pharmacology
• prevention
• surgery
• tumor

• Washington Cancer Institute, Washington Hospital Center, USA

  Paul H. Sugarbaker

Policies and ethics